Drug intelligence / Profile preview

SYP-2136

Development stage: Preclinical
Lead developer: Samyang Holdings Biopharm Group
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

SYP-2136 is a preclinical mRNA-based therapeutic candidate being developed by Samyang Holdings Biopharm Group. It utilizes the company's proprietary SENS™ (Stability Enhanced Nano-Shell) delivery technology, which is a non-viral delivery system designed to improve the stability and delivery efficiency of nucleic acids. SYP-2136 is specifically engineered for liver-targeted delivery, aiming to express therapeutic proteins within hepatocytes. While the specific disease indication and molecular target remain undisclosed (TBD), the asset is a key part of Samyang's pipeline focused on advancing mRNA therapeutics and gene-based medicines.

Beyond the preview

Go deeper on SYP-2136.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYP-2136.

Explore the full profile